Search
Methenamine
go.drugbank.com/drugs/DB06799ApprovedInvestigationalVet approvedIn salt form it is used for the treatment of urinary tract infection (Example: methenamine hippurate which is the hippuric acid salt of methenamine).
Mixtures: Non Toxic Disinfectant, UR N-C Urinary AntisepticDaridorexant
go.drugbank.com/drugs/DB15031ApprovedInvestigational[A244280] Daridorexant was approved by the European Commission on May 3, 2022, as the first dual orexin receptor antagonist approved in the market,[L41725] and by Health Canada on April 26, 2023. … [A244225] Daridorexant works on orexin receptors OX1R and OX2R to block the binding of orexins, which are wake-promoting neuropeptides and endogenous ligands to these receptors.
Padeliporfin
go.drugbank.com/drugs/DB15575ApprovedInvestigational[A244699] Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment of low-risk prostate cancer in adults meeting certain clinical criteria.[L39799]
Categories: Sensitizers Used in Photodynamic/radiation TherapyTrastuzumab
go.drugbank.com/drugs/DB00072ApprovedInvestigationalProduced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody [A40276] that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular … In Canada, biosimilars ONTRUZANT[[L40303, L40308] and Adheroza[L52835] are approved. In November 2023, trastuzumab was also approved by the EMA under the brand name Herwenda.[L49339]
Patisiran
go.drugbank.com/drugs/DB14582ApprovedPatisiran is a first in class short interfering RNA for the treatment of patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis [L4220]. … The approval for Onpattro was granted to Alnylam Pharmaceuticals, Inc. in August of 2018. Onpattro has been granted Fast Track, Priority Review and Breakthrough Therapy, and Orphan Drug designations.
Categories: Compounds used in a research, industrial, or household settingIstiratumab
go.drugbank.com/drugs/DB15363InvestigationalIstiratumab is under investigation in clinical trial NCT02399137 (A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer).
Glasdegib
go.drugbank.com/drugs/DB11978ApprovedInvestigational[A40310] Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). … Currently, the current gold standard of AML in older patients is still venetoclax with hypomethylation agents, new clinical combinations of glasdegib are being tested in hope of replacing venetoclax due
Nalmefene
go.drugbank.com/drugs/DB06230ApprovedInvestigationalWithdrawn[L1024] Nalmefene was approved in the United States in 1995 as an antidote for opioid overdose.[A245839] Nalmefene injection is used to manage known or suspected opioid overdose. … [L1024] In Europe, nalmefene oral tablets are used to reduce alcohol consumption in adults with alcohol dependence.
Categories: Drugs Used in Alcohol Dependence, Drugs Used in Addictive DisordersStreptococcus pneumoniae type 4 capsular polysaccharide antigen
go.drugbank.com/drugs/DB10322ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTOR, PNEUMOVAX 23 Injektionslösung in einer FertigspritzeBoceprevir
go.drugbank.com/drugs/DB08873ApprovedWithdrawnwith [DB00811], [DB00008], and [DB00022] as first line therapy for Hepatitis C [A19593]. … Boceprevir is available as a fixed dose product (tradename Victrelis) used for the treatment of chronic Hepatitis C.